<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04316871</url>
  </required_header>
  <id_info>
    <org_study_id>EPMDose</org_study_id>
    <nct_id>NCT04316871</nct_id>
  </id_info>
  <brief_title>Dosage of Epidural Morphine in Elderly Patients</brief_title>
  <official_title>Epidural Morphine for Elderly Patients Undergoing Lower Abdominal Cancer Surgery: a Dose Response Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This a clinical trial that evaluates the efficacy and safety of three different doses of
      morphine, namely 1.5 mg, 3 mg and 4.5 mg, via the epidural route regarding reducing pain in
      elderly patients after a cancer surgery in the lower abdomen
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acute postoperative pain is a common complaint for several days after surgery. However, acute
      postoperative pain remains even more under controlled in elderly patients, especially those
      with cognitive impairment and malignancy. Geriatric population is reported to be at higher
      risk for unwanted side effects from analgesic treatments compared to younger patients due to
      different major risk factors such as: decline in organ function, polypharmacy,
      pharmacokinetics, drug sensitivity, and frailty. Despite of the higher risk of opioids,
      especially morphine, causing toxicity and adverse effect; they are still the cornerstone
      treatment of severe acute postoperative pain. Morphine in those patients is very likely to
      cause toxicity because of accumulation of its active metabolites compared to other opioids
      with fewer or no active metabolites. Epidural morphine is an effective route for an effective
      drug. Furthermore, unwanted side effects with neuraxial opioids are minor and managed easily.
      Regarding clinical outcomes, clinical studies showed a lot of improvements associated with
      postoperative opioid analgesia. Now, there is a clinical necessity to achieve the best
      management of acute postoperative pain in elderly patients with the least possibility of
      adverse side effects. We aim in this randomized, assessor blinded, clinical trial at Assuit
      University to determine the optimum dose of epidural morphine for the highest control of
      acute postoperative pain in geriatrics who are planned to have lower abdominal cancer
      surgery.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">March 20, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total patient-controlled analgesia (PCA) morphine sulphate (MS) consumption.</measure>
    <time_frame>72 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain-intensity measured using visual analog scale (VAS)</measure>
    <time_frame>72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ramsay sedation scale (RSS).</measure>
    <time_frame>72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nausea, vomiting and pruritis scale</measure>
    <time_frame>72 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Age Problem</condition>
  <condition>Abdominal Cancer</condition>
  <arm_group>
    <arm_group_label>Group M0</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group M1.5</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group M3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group M4.5</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphine Sulfate</intervention_name>
    <description>Morphine Sulphate, 1.5 mg will be given epidurally.</description>
    <arm_group_label>Group M1.5</arm_group_label>
    <other_name>M1.5</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>Normal saline will be given epidurally.</description>
    <arm_group_label>Group M0</arm_group_label>
    <other_name>M0</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphine Sulfate</intervention_name>
    <description>Morphine Sulphate, 3 mg will be given epidurally.</description>
    <arm_group_label>Group M3</arm_group_label>
    <other_name>M3</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphine Sulfate</intervention_name>
    <description>Morphine Sulphate, 4.5 mg will be given epidurally.</description>
    <arm_group_label>Group M4.5</arm_group_label>
    <other_name>M4.5</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Men and women aged ≥ 60 years, who are planned to undergo lower abdominal cancer
             surgery.

          2. Surgeries via infra-umbilical abdominal incision is considered eligible.

        Exclusion Criteria:

          1. Patient refusal.

          2. Patients who are morbidly obese (body mass index ≥ 40 kg/m2).

          3. Those with contraindications to neuraxial analgesia.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Diab Hetta, MD</last_name>
    <role>Study Director</role>
    <affiliation>Assiut University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Muhammad Shawqi Abdelnasser, MD</last_name>
    <phone>01006895078</phone>
    <phone_ext>002</phone_ext>
    <email>m.shawqi@med.au.edu.eg</email>
  </overall_contact>
  <location>
    <facility>
      <name>Assuit University</name>
      <address>
        <city>Assuit</city>
        <zip>71515</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Muhammad Shawqi Abdelnasser, MD</last_name>
      <phone>0106895078</phone>
      <phone_ext>002</phone_ext>
      <email>m.shawqi@med.au.edu.eg</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>McKeown JL. Pain Management Issues for the Geriatric Surgical Patient. Anesthesiol Clin. 2015 Sep;33(3):563-76. doi: 10.1016/j.anclin.2015.05.010. Epub 2015 Jul 3. Review.</citation>
    <PMID>26315638</PMID>
  </reference>
  <reference>
    <citation>Palmer CM, Nogami WM, Van Maren G, Alves DM. Postcesarean epidural morphine: a dose-response study. Anesth Analg. 2000 Apr;90(4):887-91.</citation>
    <PMID>10735794</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 19, 2020</study_first_submitted>
  <study_first_submitted_qc>March 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 20, 2020</study_first_posted>
  <last_update_submitted>March 19, 2020</last_update_submitted>
  <last_update_submitted_qc>March 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Muhammad Mostafa Shawqi Abdelnasser</investigator_full_name>
    <investigator_title>Anesthesia resident at South Egypt Cancer Institute</investigator_title>
  </responsible_party>
  <keyword>Injections, Epidural</keyword>
  <keyword>Morphine Sulfate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abdominal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Morphine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

